European Generic Markets: Regulatory Approaches Across the EU in 2026

When you pick up a generic pill at your pharmacy in Berlin, Paris, or Warsaw, you might assume it’s just like the brand-name version. But behind that simple exchange is one of the most complex regulatory systems in the world. In the European Union, getting a generic drug to market isn’t just about proving it works-it’s about navigating four different approval paths, 27 national rules, and a major overhaul that took effect in 2025. This isn’t theory. It’s daily reality for manufacturers, pharmacists, and patients alike.

How Generic Drugs Get Approved in the EU

The EU doesn’t have one single way to approve generic medicines. Instead, it offers four distinct pathways, each with different costs, timelines, and risks. These aren’t just bureaucratic options-they shape whether a drug reaches patients in six months or two years.

The Centralized Procedure is the fastest route to EU-wide access. A company submits one application to the European Medicines Agency (EMA), and if approved, the drug can be sold in all 27 EU countries plus Iceland, Liechtenstein, and Norway. This path takes about 180 days under the 2025 reforms-down from 210-and the European Commission must issue authorization within 46 days. But there’s a catch: it costs between €1.6 million and €2.2 million in fees and consultancy alone. Only companies targeting high-volume drugs-those expected to earn over €250 million annually-use this route. Sandoz did it right with their Cosentyx generic, launching across the entire EU in Q2 2025, 11 months faster than the traditional route.

Then there’s the Mutual Recognition Procedure (MRP), used in 42% of cases. Here, a company gets approval in one country-the Reference Member State-and asks others to accept it. Sounds simple, right? Not always. In practice, countries often add their own demands. Teva’s 2023 launch of a generic rosuvastatin hit a wall when Germany delayed pricing talks, which held up market entry in the Netherlands and Belgium for over eight months. Even after technical approval, national reimbursement rules can block access.

The Decentralized Procedure (DCP) lets companies apply to multiple countries at once, without prior approval anywhere. It’s meant to speed things up, but it often backfires. A 2024 study found that 37% of DCP applications took more than six months longer than expected. Why? Because Eastern European regulators sometimes demand extra stability data or different bioequivalence thresholds than the EMA. One company reported their DCP submission stalled for 14 months because Poland and Romania requested additional clinical data that didn’t exist in the original dossier.

Finally, the National Procedure is the old-school route: apply in one country only. It’s used for just 5% of applications, mostly by small firms targeting a single high-reimbursement market. But even here, delays are common. Accord Healthcare’s 2024 experience in France took 197 days-nearly two months longer than the same drug approved via MRP across five countries.

What Makes a Generic ‘Equivalent’?

Before any pathway even starts, a generic must prove it’s identical to the original. The EMA requires three things: same active ingredients, same dosage form, and proven bioequivalence. That last part is where most battles are fought.

Bioequivalence means the generic must deliver the same amount of drug into the bloodstream at the same rate as the brand. Studies must show that the 90% confidence interval for two key measurements-Cmax (peak concentration) and AUC (total exposure)-falls between 80% and 125%. This isn’t just a guideline; it’s legally binding. The 2025 update to the EMA’s Bioequivalence Guideline tightened standards for complex drugs like inhalers and extended-release tablets. Germany’s BfArM now requires extra pharmacodynamic testing for inhalers that other countries don’t. That means a company might pass EMA standards but still get rejected in Germany.

Even small differences matter. If a generic uses a different salt form, coating, or manufacturing process, regulators may demand additional studies. One company spent €1.3 million and 18 months on a single reformulation because the original reference product had a polymorphic crystal structure that their version didn’t match. That’s not rare-it’s routine.

The 2025 Pharma Package: What Changed

The biggest shift since 2004 came with the EU Pharma Package, finalized on June 4, 2025. It didn’t just tweak rules-it rewrote the game.

The most talked-about change is the expanded Bolar exemption. Before 2025, companies could only start pricing and reimbursement talks with health authorities two months before a patent expired. Now, they can start six months ahead. This might sound minor, but it’s huge. REMAP Consulting estimates this alone will cut generic launch delays by 4.3 months on average. It gives payers more time to negotiate prices, which means generics may launch at lower prices-but also with less uncertainty.

Another key reform: Regulatory Data Protection was reduced from 10 years to 8 years of data exclusivity, plus one year of market exclusivity (extendable to two years if the drug meets public health goals). This means competitors can file for approval sooner. For high-value biologics, Evaluate Pharma predicts 78 products will see generic entry accelerated by this change alone.

There’s also the obligation to supply rule. If a company holds a generic license and there’s a shortage, regulators can now require them to produce enough to meet demand. Sounds fair? Maybe. But Professor Panos Kanavos of LSE Health warns that national authorities interpret “sufficient quantities” differently. A company might be forced to ramp up production in France while being allowed to hold back in Lithuania. That creates new risks-and new legal headaches.

And then there’s the electronic product information (ePI) mandate. By 2026, every generic must submit its patient leaflet in XML format. This isn’t just paperwork-it requires IT upgrades. White & Case estimates this will cost companies between €180,000 and €250,000 in system changes. Small firms are feeling the pinch.

Who’s Winning and Who’s Struggling

The EU generics market was worth €42.7 billion in 2024, growing at 6.2%. But not everyone is benefiting equally.

Indian manufacturers now hold 38% of all EU generic approvals, up from 29% in 2020. Their strength? Low-cost production and aggressive filings. They dominate in simple oral tablets and injectables. But they struggle with complex drugs-where regulatory requirements are stricter and testing costs are higher.

European firms like Sandoz and Viatris still lead with 52% of approvals. Their secret? They use the Centralized Procedure strategically. They don’t just file-they plan. They invest in early-stage bioequivalence studies, build relationships with EMA assessors, and prepare for the 15- to 18-month lead time needed for a successful submission.

Smaller European companies? They’re squeezed. The €490 million sales threshold for Transferable Exclusivity Vouchers-another 2025 reform-means only the biggest players can trade market exclusivity rights. Mid-sized firms can’t compete on scale, and they can’t afford the cost of the Centralized Procedure. Many are shifting to niche markets or national approvals, but that limits their growth.

What’s Next for Generic Access?

The 2025 reforms are just the beginning. The Critical Medicines Act of March 2025 added mandatory stockpiling for 200 essential generics. That’s meant to prevent shortages, but it also means new quality checks, more inspections, and higher compliance costs.

The US-EU Framework Agreement, effective September 1, 2025, may lower tariffs on key pharmaceutical ingredients. But its impact is still unclear. Will it cut costs for generic makers? Or just shift supply chains without lowering prices?

One thing is certain: the gap between U.S. and EU generic launch times is still too wide. The average delay is 22.4 months. In Canada? Just 8.7 months. That’s not a coincidence-it’s policy. The EU’s fragmented system, even after 2025, still creates bottlenecks.

Patients want faster access. Payors want lower prices. Manufacturers want predictability. The system tries to serve all three-but too often, it serves none perfectly. The 2025 reforms were a step forward. But until national authorities stop adding their own rules on top of EU standards, the system will remain a maze.